Reply to Yoshida: Liver cancer stem cells: Identification and lipid metabolic reprogramming [Biological Sciences]

As a molecular basis by which acyclic retinoid (ACR) prevents recurrence of hepatocellular carcinoma (HCC), we identify MYCN+ liver cancer stem cell (CSC)-like cell serves as a biomarker and therapeutic target to be selectively eliminated by ACR (1). In the Letter by Yoshida (2), the author makes two important comments...

https://ift.tt/2un0Hsx